{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:16:58Z","timestamp":1793121418842,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03963-3","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:26:40Z","timestamp":1756286800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Revisiting the role of local treatments in the era of targeted therapy and immunotherapy for hepatocellular carcinoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Jia-jia","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zun-yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Er-lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"3963_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","volume":"156","author":"L Kulik","year":"2019","unstructured":"Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156:477\u2013e4911.","journal-title":"Gastroenterology"},{"key":"3963_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.","journal-title":"Nat Rev Dis Primers"},{"key":"3963_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681\u201393.","journal-title":"J Hepatol"},{"key":"3963_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"3963_CR5","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.3748\/wjg.v28.i28.3573","volume":"28","author":"LG da Fonseca","year":"2022","unstructured":"da Fonseca LG, Araujo RLC. Combination approaches in hepatocellular carcinoma: how systemic treatment can benefit candidates to locoregional modalities. World J Gastroenterol. 2022;28:3573\u201385.","journal-title":"World J Gastroenterol"},{"key":"3963_CR6","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68:723\u201350.","journal-title":"Hepatology"},{"key":"3963_CR7","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1053\/j.gastro.2018.09.051","volume":"156","author":"TF Greten","year":"2019","unstructured":"Greten TF, Lai CW, Li G, et al. Targeted and immune-based therapies for hepatocellular carcinoma. Gastroenterology. 2019;156:510\u201324.","journal-title":"Gastroenterology"},{"issue":"2","key":"3963_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jhep.2019.11.006","volume":"72","author":"JC Nault","year":"2020","unstructured":"Nault JC, Cheng AL, Sangro B, et al. Milestones in the pathogenesis and management of primary liver cancer. J Hepatol. 2020;72(2):209\u201314.","journal-title":"J Hepatol"},{"key":"3963_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2017.12.002","volume":"52","author":"PS Hegde","year":"2018","unstructured":"Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol. 2018;52:117\u201324.","journal-title":"Semin Cancer Biol"},{"key":"3963_CR10","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862\u201373.","journal-title":"J Hepatol"},{"key":"3963_CR11","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1200\/JCO.20.03555","volume":"39","author":"RK Kelley","year":"2021","unstructured":"Kelley RK, Sangro B, Harris W, et al. Safety, efficacy, and pharmacodynamics of Tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study. J Clin Oncol. 2021;39:2991\u20133001.","journal-title":"J Clin Oncol"},{"key":"3963_CR12","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450\u201362.","journal-title":"N Engl J Med"},{"key":"3963_CR13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/SLA.0000000000002360","volume":"266","author":"J Zheng","year":"2017","unstructured":"Zheng J, Chou JF, G\u00f6nen M, et al. Prediction of hepatocellular carcinoma recurrence beyond Milan criteria after resection: validation of a clinical risk score in an international cohort. Ann Surg. 2017;266:693\u2013701.","journal-title":"Ann Surg"},{"key":"3963_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/01.sla.0000197706.21803.a1","volume":"243","author":"N Portolani","year":"2006","unstructured":"Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229\u201335.","journal-title":"Ann Surg"},{"key":"3963_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1055-3207(02)00090-X","volume":"12","author":"R Kianmanesh","year":"2003","unstructured":"Kianmanesh R, Regimbeau JM, Belghiti J. Selective approach to major hepatic resection for hepatocellular carcinoma in chronic liver disease. Surg Oncol Clin North Am. 2003;12:51\u201363.","journal-title":"Surg Oncol Clin North Am"},{"key":"3963_CR16","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2147\/JHC.S357313","volume":"9","author":"Z Yin","year":"2022","unstructured":"Yin Z, Chen D, Liang S, et al. Neoadjuvant therapy for hepatocellular carcinoma. J Hepatocell Carcinoma. 2022;9:929\u201346.","journal-title":"J Hepatocell Carcinoma"},{"key":"3963_CR17","doi-asserted-by":"publisher","first-page":"e004656","DOI":"10.1136\/jitc-2022-004656","volume":"10","author":"Y Xia","year":"2022","unstructured":"Xia Y, Tang W, Qian X, et al. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer. 2022;10:e004656.","journal-title":"J Immunother Cancer"},{"key":"3963_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S2468-1253(21)00385-X","volume":"7","author":"TU Marron","year":"2022","unstructured":"Marron TU, Fiel MI, Hamon P, et al. Neoadjuvant Cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7:219\u201329.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3963_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","volume":"7","author":"AO Kaseb","year":"2022","unstructured":"Kaseb AO, Hasanov E, Cao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7:208\u201318.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3963_CR20","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2147\/JHC.S332420","volume":"8","author":"JY Wu","year":"2021","unstructured":"Wu JY, Yin ZY, Bai YN, et al. Lenvatinib combined with Anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A multicenter retrospective study. J Hepatocell Carcinoma. 2021;8:1233\u201340.","journal-title":"J Hepatocell Carcinoma"},{"key":"3963_CR21","doi-asserted-by":"crossref","unstructured":"D\u2019Alessio A, Pai M, Spalding D, et al. Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: the PRIME-HCC trial. J Clin Oncol. 2022;40:4093.","DOI":"10.1200\/JCO.2022.40.16_suppl.4093"},{"key":"3963_CR22","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","volume":"2","author":"WJ Ho","year":"2021","unstructured":"Ho WJ, Zhu Q, Durham J, et al. Neoadjuvant Cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat Cancer. 2021;2:891\u2013903.","journal-title":"Nat Cancer"},{"key":"3963_CR23","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000514313","volume":"10","author":"XD Zhu","year":"2021","unstructured":"Zhu XD, Huang C, Shen YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations. Liver Cancer. 2021;10:320\u20139.","journal-title":"Liver Cancer"},{"key":"3963_CR24","doi-asserted-by":"crossref","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u20131173.","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"3963_CR25","doi-asserted-by":"crossref","unstructured":"Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56\u201366.","DOI":"10.1016\/S0140-6736(16)32453-9"},{"key":"3963_CR26","doi-asserted-by":"crossref","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Kl\u00fcmpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018;379(1):54\u201363.","DOI":"10.1056\/NEJMoa1717002"},{"key":"3963_CR27","doi-asserted-by":"crossref","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894\u20131905.","DOI":"10.1056\/NEJMoa1915745"},{"key":"3963_CR28","doi-asserted-by":"crossref","unstructured":"Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282\u2013296.","DOI":"10.1016\/S1470-2045(18)30937-9"},{"key":"3963_CR29","doi-asserted-by":"crossref","unstructured":"Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL; KEYNOTE-240 investigators. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020;38(3):193\u2013202.","DOI":"10.1200\/JCO.19.01307"},{"key":"3963_CR30","doi-asserted-by":"crossref","unstructured":"Wu JY, Wu JY, Li YN, Qiu FN, Zhou SQ, Yin ZY, Chen YF, Li B, Zhou JY, Yan ML. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A multicenter retrospective study. Front Oncol. 2022;12:985380.","DOI":"10.3389\/fonc.2022.985380"},{"key":"3963_CR31","doi-asserted-by":"publisher","first-page":"S1541","DOI":"10.1016\/j.annonc.2023.10.304","volume":"34","author":"K Wang","year":"2023","unstructured":"Wang K, Sun H, Bai X, et al. Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with Atezolizumab plus bevacizumab. Ann Oncol. 2023;34:S1541.","journal-title":"Ann Oncol"},{"key":"3963_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1055\/s-0041-1730949","volume":"41","author":"YY Su","year":"2021","unstructured":"Su YY, Li CC, Lin YJ, et al. Adjuvant versus neoadjuvant immunotherapy for hepatocellular carcinoma: clinical and immunologic perspectives. Semin Liver Dis. 2021;41:263\u201376.","journal-title":"Semin Liver Dis"},{"key":"3963_CR33","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","volume":"16","author":"J Bruix","year":"2015","unstructured":"Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344\u201354.","journal-title":"Lancet Oncol"},{"key":"3963_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/JHC.S352480","volume":"9","author":"K Lin","year":"2022","unstructured":"Lin K, Wei F, Huang Q, et al. Postoperative adjuvant transarterial chemoembolization plus tyrosine kinase inhibitor for hepatocellular carcinoma: a multicentre retrospective study. J Hepatocell Carcinoma. 2022;9:127\u201340.","journal-title":"J Hepatocell Carcinoma"},{"key":"3963_CR35","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1158\/1078-0432.CCR-03-0071","volume":"10","author":"M Kuang","year":"2004","unstructured":"Kuang M, Peng BG, Lu MD, et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004;10:1574\u20139.","journal-title":"Clin Cancer Res"},{"key":"3963_CR36","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S0140-6736(00)02654-4","volume":"356","author":"T Takayama","year":"2000","unstructured":"Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000;356:802\u20137.","journal-title":"Lancet"},{"key":"3963_CR37","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2015.02.055","volume":"148","author":"JH Lee","year":"2015","unstructured":"Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015;148:1383\u201391.","journal-title":"Gastroenterology"},{"key":"3963_CR38","doi-asserted-by":"publisher","first-page":"e1328335","DOI":"10.1080\/2162402X.2017.1328335","volume":"6","author":"JH Lee","year":"2017","unstructured":"Lee JH, Tak WY, Lee Y, et al. Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study. Oncoimmunology. 2017;6:e1328335.","journal-title":"Oncoimmunology"},{"key":"3963_CR39","doi-asserted-by":"crossref","unstructured":"Xia F, Wu LL, Lau WY, Huan HB, Wen XD, Ma KS, Li XW, Bie P. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. World J Gastroenterol. 2016;22(23):5384\u201392.","DOI":"10.3748\/wjg.v22.i23.5384"},{"key":"3963_CR40","doi-asserted-by":"crossref","unstructured":"Li J, Hou Y, Cai XB, Liu B. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. World J Gastroenterol. 2016;22(15):4034\u201340.","DOI":"10.3748\/wjg.v22.i15.4034"},{"key":"3963_CR41","doi-asserted-by":"crossref","unstructured":"Li X, Xia F. Immunotherapy for hepatocellular carcinoma: molecular pathogenesis and clinical research progress. Oncol Translational Med. 2023;9(5):206\u2013212.","DOI":"10.1097\/ot9.0000000000000013"},{"key":"3963_CR42","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.jhep.2018.08.027","volume":"69","author":"AWH Chan","year":"2018","unstructured":"Chan AWH, Zhong J, Berhane S, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol. 2018;69:1284\u201393.","journal-title":"J Hepatol"},{"key":"3963_CR43","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chen M, Cheng AL, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1835\u201347.","journal-title":"Lancet"},{"key":"3963_CR44","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11684-021-0848-3","volume":"15","author":"W Zhang","year":"2021","unstructured":"Zhang W, Zhang B, Chen XP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med. 2021;15:155\u201369.","journal-title":"Front Med"},{"key":"3963_CR45","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","volume":"66","author":"AG Duffy","year":"2017","unstructured":"Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66:545\u201351.","journal-title":"J Hepatol"},{"key":"3963_CR46","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","volume":"69","author":"M Kudo","year":"2020","unstructured":"Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus Sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69:1492\u2013501.","journal-title":"Gut"},{"key":"3963_CR47","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","volume":"2","author":"T Meyer","year":"2017","unstructured":"Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:565\u201375.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3963_CR48","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1002\/hep.27290","volume":"60","author":"M Kudo","year":"2014","unstructured":"Kudo M, Han G, Finn RS, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology. 2014;60:1697\u2013707.","journal-title":"Hepatology"},{"key":"3963_CR49","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2147\/JHC.S399135","volume":"10","author":"X Yang","year":"2023","unstructured":"Yang X, Deng H, Sun Y, et al. Efficacy and safety of regorafenib plus immune checkpoint inhibitors with or without TACE as a Second-Line treatment for advanced hepatocellular carcinoma: A propensity score matching analysis. J Hepatocell Carcinoma. 2023;10:303\u201313.","journal-title":"J Hepatocell Carcinoma"},{"key":"3963_CR50","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S2468-1253(22)00339-9","volume":"8","author":"CL Chiang","year":"2023","unstructured":"Chiang CL, Chiu KWH, Chan KSK, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:169\u201378.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"3963_CR51","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","volume":"71","author":"J Ricke","year":"2019","unstructured":"Ricke J, Kl\u00fcmpen HJ, Amthauer H, et al. Impact of combined selective internal radiation therapy and Sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(6):1164\u201374.","journal-title":"J Hepatol"},{"key":"3963_CR52","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","volume":"6","author":"D Tai","year":"2021","unstructured":"Tai D, Loke K, Gogna A, et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209\u2013678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6:1025\u201335.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3963_CR53","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S2468-1253(18)30078-5","volume":"3","author":"M Kudo","year":"2018","unstructured":"Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus Sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3:424\u201332.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3963_CR54","doi-asserted-by":"crossref","unstructured":"de la Torre-Al\u00e1ez M, Matilla A, Varela M, I\u00f1arrairaegui M, Reig M, Lled\u00f3 JL, Arenas JI, Lorente S, Testillano M, M\u00e1rquez L, Da Fonseca L, Argem\u00ed J, G\u00f3mez-Martin C, Rodriguez-Fraile M, Bilbao JI, Sangro B. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. J Immunother Cancer. 2022;10(11):e005457.","DOI":"10.1136\/jitc-2022-005457"},{"key":"3963_CR55","doi-asserted-by":"crossref","unstructured":"Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47(14):2117\u201327.","DOI":"10.1016\/j.ejca.2011.05.007"},{"key":"3963_CR56","doi-asserted-by":"crossref","unstructured":"Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, Luca A, Del Arbol LR, Leberre MA, Niu W, Nicholson K, Meinhardt G, Bruix J. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol. 2016;64(5):1090\u20131098.","DOI":"10.1016\/j.jhep.2016.01.012"},{"key":"3963_CR57","doi-asserted-by":"crossref","unstructured":"Kudo M, Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, Izumi N, Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S, Arai Y. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol. 2018;3(1):37\u201346.","DOI":"10.1016\/S2468-1253(17)30290-X"},{"key":"3963_CR58","doi-asserted-by":"crossref","unstructured":"Park JW, Kim YJ, Kim DY, Bae SH, Paik SW, Lee YJ, Kim HY, Lee HC, Han SY, Cheong JY, Kwon OS, Yeon JE, Kim BH, Hwang J. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. J Hepatol. 2019;70(4):684\u2013691.","DOI":"10.1016\/j.jhep.2018.11.029"},{"key":"3963_CR59","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:293\u2013313.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3963_CR60","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1053\/j.gastro.2009.12.051","volume":"138","author":"A Zerbini","year":"2010","unstructured":"Zerbini A, Pilli M, Laccabue D, et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology. 2010;138:1931\u201342.","journal-title":"Gastroenterology"},{"key":"3963_CR61","doi-asserted-by":"crossref","unstructured":"Liu X, Zhang W, Xu Y, et al. Targeting PI3K\u03b3\/AKT pathway remodels LC3-Associated phagocytosis induced immunosuppression after radiofrequency ablation. Adv Sci (Weinh). 2022;9:e2102182.","DOI":"10.1002\/advs.202102182"},{"key":"3963_CR62","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1148\/radiol.11081489","volume":"259","author":"RJ Lewandowski","year":"2011","unstructured":"Lewandowski RJ, Geschwind JF, Liapi E, et al. Transcatheter intraarterial therapies: rationale and overview. Radiology. 2011;259:641\u201357.","journal-title":"Radiology"},{"issue":"Suppl 1","key":"3963_CR63","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/hep.31424","volume":"73","author":"R Kloeckner","year":"2021","unstructured":"Kloeckner R, Galle PR, Bruix J. Local and regional therapies for hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):137\u201349.","journal-title":"Hepatology"},{"key":"3963_CR64","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/cncr.27859","volume":"119","author":"M Buijs","year":"2013","unstructured":"Buijs M, Reyes DK, Pawlik TM, et al. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2013;119:1042\u20139.","journal-title":"Cancer"},{"key":"3963_CR65","doi-asserted-by":"publisher","first-page":"e004205","DOI":"10.1136\/jitc-2021-004205","volume":"10","author":"B Marinelli","year":"2022","unstructured":"Marinelli B, Kim E, D\u2019Alessio A, et al. Integrated use of PD-1 Inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer. 2022;10:e004205.","journal-title":"J Immunother Cancer"},{"key":"3963_CR66","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3390\/cancers13020192","volume":"13","author":"LA P\u00e9rez-Romasanta","year":"2021","unstructured":"P\u00e9rez-Romasanta LA, Gonz\u00e1lez-Del Portillo E, Rodr\u00edguez-Guti\u00e9rrez A, et al. Stereotactic radiotherapy for hepatocellular carcinoma, radiosensitization strategies and Radiation-Immunotherapy combination. Cancers (Basel). 2021;13:192.","journal-title":"Cancers (Basel)"},{"key":"3963_CR67","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1158\/1078-0432.CCR-14-2824","volume":"21","author":"A Filatenkov","year":"2015","unstructured":"Filatenkov A, Baker J, Mueller AM, et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res. 2015;21:3727\u201339.","journal-title":"Clin Cancer Res"},{"key":"3963_CR68","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/13543784.2022.2009455","volume":"31","author":"A Di Federico","year":"2022","unstructured":"Di Federico A, Rizzo A, Carloni R, et al. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. Expert Opin Investig Drugs. 2022;31:361\u20139.","journal-title":"Expert Opin Investig Drugs"},{"key":"3963_CR69","first-page":"1","volume":"3","author":"A Mahvash","year":"2016","unstructured":"Mahvash A, Murthy R, Odisio BC, et al. Yttrium-90 resin microspheres as an adjunct to Sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma. 2016;3:1\u20137.","journal-title":"J Hepatocell Carcinoma"},{"key":"3963_CR70","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/13543784.2021.1948532","volume":"31","author":"A Rizzo","year":"2022","unstructured":"Rizzo A, Dadduzio V, Ricci AD, et al. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? Expert Opin Investig Drugs. 2022;31:371\u20138.","journal-title":"Expert Opin Investig Drugs"},{"key":"3963_CR71","doi-asserted-by":"publisher","first-page":"137","DOI":"10.21037\/hbsn-22-545","volume":"12","author":"EL Zhang","year":"2023","unstructured":"Zhang EL, Zhang ZY, Huang ZY. Splenectomy may facilitate systemic therapy for advanced hepatocellular carcinoma with hypersplenism. Hepatobiliary Surg Nutr. 2023;12:137\u20139.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"3963_CR72","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood-2016-04-692665","volume":"128","author":"T Lisman","year":"2016","unstructured":"Lisman T, Porte RJ. Mechanisms of platelet-mediated liver regeneration. Blood. 2016;128:625\u20139.","journal-title":"Blood"},{"key":"3963_CR73","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.3748\/wjg.v19.i32.5250","volume":"19","author":"K Takahashi","year":"2013","unstructured":"Takahashi K, Murata S, Fukunaga K, et al. Human platelets inhibit liver fibrosis in severe combined immunodeficiency mice. World J Gastroenterol. 2013;19:5250\u201360.","journal-title":"World J Gastroenterol"},{"key":"3963_CR74","doi-asserted-by":"publisher","first-page":"e00058","DOI":"10.14309\/ctg.0000000000000058","volume":"10","author":"Z Macek Jilkova","year":"2019","unstructured":"Macek Jilkova Z, Aspord C, Kurma K, et al. Immunologic features of patients with advanced hepatocellular carcinoma before and during sorafenib or anti-programmed death-1\/programmed death-L1 treatment. Clin Transl Gastroenterol. 2019;10:e00058.","journal-title":"Clin Transl Gastroenterol"},{"key":"3963_CR75","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00262-019-02299-8","volume":"68","author":"D Agdashian","year":"2019","unstructured":"Agdashian D, ElGindi M, Xie C, et al. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2019;68:599\u2013608.","journal-title":"Cancer Immunol Immunother"},{"key":"3963_CR76","doi-asserted-by":"publisher","first-page":"e0004306","DOI":"10.1371\/journal.pntd.0004306","volume":"10","author":"A Romano","year":"2016","unstructured":"Romano A, Hou X, Sertorio M, et al. FOXP3\u2009+\u2009regulatory T cells in hepatic fibrosis and splenomegaly caused by schistosoma japonicum: the spleen may be a major source of Tregs in subjects with splenomegaly. PLoS Negl Trop Dis. 2016;10:e0004306.","journal-title":"PLoS Negl Trop Dis"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03963-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03963-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03963-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T19:43:31Z","timestamp":1757447011000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03963-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3963"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03963-3","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"323"}}